Program data from Project HCV Connect captured 344 Los Angeles County case-residents contacted between October 2024 and January 2025. Data indicated that 168 people (49%) were already treated and 176 had not received treatment at the time of contact. The study team reported that 54% of case-residents experienced at least one barrier to starting treatment. Among those who reported specific barriers (n = 91), investigators grouped responses into four categories: personal barriers (43%), provider-related barriers (31%), insurance barriers (13%), and inadequate access to medical care (13%).
The quantitative approach used descriptive frequencies and percentages only. The authors did not perform inferential statistics because many barrier sub-categories had small cell sizes (n < 15), which they judged insufficient for robust hypothesis testing. The program data included demographic fields and treatment status; it did not, however, offer causal explanations for why particular barriers clustered in certain subgroups.
The qualitative component involved ten semi-structured interviews: seven untreated and three treated participants. Interviews were conducted in English and Spanish and analyzed with an inductive coding process. Untreated participants raised a mix of personal and structural obstacles. Short, stark realities emerged: homelessness, recent incarceration, and active drug use—each named directly as impediments to pursuing HCV care. Other participants emphasized financial instability and the perceived high cost of treatment. Several Spanish-speaking respondents specifically flagged cost as a primary deterrent.
Participants recounted problems with provider interactions. Some described incomplete follow-up after an initial visit and long waits to see clinicians. Others said they felt dismissed or treated impersonally, which discouraged further engagement with care. Language barriers surfaced repeatedly among Spanish-speaking interviewees: unclear explanations, medication materials in English, and a lack of Spanish-speaking clinicians or interpreters led some to disengage. One untreated Spanish-speaking participant recounted switching to a Spanish-speaking primary care doctor who provided clearer explanations and improved understanding.
Practical access issues were also documented. Transportation problems and difficulties with required blood draws (for example, collapsed veins after prior IV drug use) were offered as reasons that diagnostic processes and subsequent treatment initiation were delayed or abandoned. Interview excerpts in the source highlight how system navigation frustrations—scheduling, repeated attempts, and multiple visits—drove participants away from completing the linkage-to-care pathway.
Interviewed participants who pursued or completed treatment identified several enabling factors. Personal motivation to get cured and protect one’s health was a consistent driver. Family and community support provided tangible encouragement for scheduling and attending visits. Trust in a clinician—when present—helped participants feel safe to start therapy. Adequate insurance coverage was cited as a practical facilitator; conversely, concerns about cost and insurance limitations appeared among barriers.
Understanding the benefits of HCV treatment emerged as an important facilitator. Several participants said that clearer, accessible information about curative therapy influenced their readiness to pursue treatment. The desire to avoid stigma and to resolve a known infection also motivated some people to complete linkage steps. These facilitators mirror the programmatic categories but add depth about the psychosocial and informational elements that enable treatment uptake.
Investigators and participants suggested concrete strategies that align with the barriers and facilitators observed. Language support services and bilingual clinical staff were recommended to reduce communication gaps identified by Spanish-speaking residents. Patient navigation and care coordination were proposed to help people traverse scheduling, follow-up, and insurance processes. Mobile clinics and outreach models were advanced as ways to reach unhoused populations and to perform necessary testing and treatment in nontraditional settings. Ensuring continuity of care for people re-entering the community after incarceration was raised as a systems-level priority.
The source also recommended policy-level changes. Specifically, removing insurance restrictions, such as prior authorization requirements, was described as a potential way to lower administrative obstacles. The linkage-to-cure program’s data were used to anchor these recommendations, but the programmatic dataset itself could not test the effectiveness of any particular intervention.
The authors acknowledged several limitations in their report. Quantitative analyses were descriptive only; inferential tests were not conducted because many subcategory counts were small (n < 15). The qualitative sample was small (ten interviews), and member-checking or participant transcript validation was not performed. Interview recruitment was purposive and drawn from the linkage-to-cure population, which may limit generalizability to other LA County residents not reached by the program. The source did not report longitudinal follow-up to measure whether suggested program strategies improved treatment initiation or completion.
Remaining questions documented by the study team include whether language services and navigation would measurably increase treatment rates among Spanish-speaking and unhoused individuals, and how best to operationalize continuity of care for people leaving incarceration. The program data, while informative about barrier frequency, did not provide causal inference or intervention outcomes—areas that the authors indicated warrant further research.